{Reference Type}: Case Reports
{Title}: Shallow periorbital injection of triamcinolone acetonide in treatment of lower eyelid entropion related to thyroid-associated ophthalmopathy: Three case reports.
{Author}: Mo F;Xu D;Xu H;Li G;Gao Y;Li H;
{Journal}: Medicine (Baltimore)
{Volume}: 99
{Issue}: 5
{Year}: Jan 2020
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000019026
{Abstract}: <B>BACKGROUND: </B>Entropion and secondary trichiasis can lead to irritative symptoms and essential damage of ocular surface. There is no literature reporting the lower eyelid entropion related to thyroid-associated ophthalmopathy (TAO), let alone the treatment. Treatment based on etiology may yield effective and sustained results. We report 3 case reports of lower eyelid entropion associated with TAO, and provide an effective and persistent alternative to cure this entropion via the administration of shallow periorbital injections of triamcinolone acetonide (TA).<BR><B>METHODS: </B>Three patients presented irritative symptoms of ocular surface and diplopia.<BR><B>METHODS: </B>According to thyroid dysfunction, physical examination, and imaging findings of extraocular muscle involvement, TAO and unilateral or bilateral lower eyelid entropion were diagnosed.<BR><B>METHODS: </B>We administered shallow periorbital injections of TA to the affected eye at 3- to 4-week intervals depending on clinical response.<BR><B>RESULTS: </B>All patients underwent complete correction of the lower eyelid entropion and no recurrence was found.<BR><B>CONCLUSIONS: </B>The cause of lower eyelid entropion related to TAO might be the immunoinflammatory reaction of the lower eyelid retractors, enhancing the traction of pulling the lower eyelid inferoposteriorly. This condition can be treated with shallow periorbital injections of TA. Histopathological evidence and randomized controlled trials are expected to confirm our hypothesis.